The economic burden of irritable bowel syndrome in Canada

Abstract

In the treatment of irritable bowel syndrome (IBS), medical practitioners and policymakers face the task of providing both high quality and cost effective medical care for a condition with no certain cure. To date, studies have examined only total medical costs to patients with symptoms consistent with an IBS diagnosis. However, these studies have not examined the direct and indirect costs incurred in the course of treatment for IBS, excluding the costs of unrelated medical conditions. Because patients with IBS have been shown to differ significantly from non-IBS patients in their desire to seek medical care, one cannot consider solely the cost differential in medical costs for IBS and non-IBS patients. The present study examines a set of patients who have been diagnosed with IBS and seek medical care for IBS.